realmediaeditor(大学毕业后从事的是记者行业)

1. realmediaeditor，大学毕业后从事的是记者行业？

根据目前的澳洲移民政策，新闻媒体记者类的职业根本无法一步到位获得移民签证，接下来我来介绍1年学习项目，申请者可以通过1年学习获得移民签证。

适用职业类别

 总监-电影电视广播舞台director (film, television, radio or stage) 212312

 编辑-电影视频 film and video editor 212314

 电视广播节目导演 program director (television or radio) 212315

 剧务 stage manager 212316

 技术总监technical director 212317

 视频制作video producer 212318

 （广告）文案copywriter 212411

 报纸或期刊编辑newspaper or periodical editor 212412

 报纸杂志记者print journalist 212413

 技术撰稿人technical writer 212415

 电视记者television journalist 212416

 其他新闻和撰稿人journalists and other writers (nec) 212499

以上新闻媒体类职业，都属于短期技术移民职业清单STSOL的职业，申请者只有获得某个州或领地的担保才可能获得190/489/491类移民签证。

目前，上述职业中，对于境外的申请者，都暂时无法一步到位获得境外的政府担保。

因此，我们介绍一种快捷的移民出路：

通过1年的学习获得州政府的担保，从而获得移民签证。

适用人群

具有学士学位

至少有1年相关经验（如果本科为非相关专业，需要至少3年经验）

移民方案

首先，需要申请者凭借自己的本科专业和工作经验，通过上述相关职业的职业评估（VETASSESS）。通过评估需要满足：

 学士学位

 至少有最近5年中1年相关经验（如果本科为非相关专业，需要至少3年经验）

 具有完整的单位社保或个人所得税缴纳记录

通过评估后，通过一年的TAS Uni 学习来满足TAS 491洲担保的要求：

1. 45周岁以下（注意是1年学习毕业后的年龄）

2. 在TAS完成至少1年的学习

3. 申请担保前居住在TAS

4. 满足65分（加政府担保分）

方案优势：时间短，获得担保概率高

经济投入：1年学费+生活费（大概在20-30万人民币）

学习内容

新闻传媒研究生文凭

Graduate Diploma of Jounalism, Media and Communications (R6I)

开学时间：2月，7月

学费：30450AUD

学制：1年

申请程序

Step 1. 申请VETASSESS 职业评估

Step 2. 通过英语考试(A类雅思或PTE)

Step 3. 申请学校Offer

Step 4. 申请学生签证

Step 5. 塔斯马尼亚大学学习1年

Step 6. 毕业申请TAS491担保

Step 7. 获得签证邀请

Step 8. 递交签证申请

Step 9. 批准

特别提醒

1. 职业评估一定要在留学签证申请前做好

2. 拿到学生签证前尽量不要辞职

3. 在澳洲学习不满2年，没有澳洲学历的加分（要求2年），一年学习只是为你获得491担保的一张门票

4. 提前了解前TAS的担保政策

5. 对于不满足65分的申请者，请提前规划好其他加分选项（例如配偶加分，提高英语等）

6. TAS 学习1年只可以获得489/491担保，学习2年才可以获得190担保

realmediaeditor(大学毕业后从事的是记者行业)

2. 你们平时都用什么工具来辅助自己？

此类工具其实非常多，百度一下基本都是【新媒体必备的N个工具】，虽然全，但建议性不高，大家传来传去也不知道优势在哪里。

这里每种类型工具只推荐一种，而且是小编深度用后最喜欢的，希望大家喜欢：

协作文档：石墨文档

相比较在QQ、微信上把Word传来传去，使用在线文档可以直接传送链接，并且领导可以在上面批注，非常方便；

数据收集：简道云 jiandaoyun.com

工作中不免会遇到一些数据收集的场景，用excel传来传去到底麻烦，简道云表单很好地解决了这个问题。

和市面大多表单不同的是，数据收集算是简道云比较简单的功能，简道云更多用在门店管理、报名登记、进销存等各种复杂应用的搭建上。也是因为支持搭建的复杂应用比较多，所以相比较同类表单，简道云开放的免费容量比较大，赠送5万免费数据量（大家可以对比下同类表单，简道云开放的免费版容量算相当高了）排版工具：135编辑器这是微信文章排版工具，135编辑器算是同类中样式非常多的平台了。HTML5场景：兔展各种H5邀请函的生成，兔展申请个企业账号就能去logo，免费版很实用。美图查找：花瓣

全中文、免费下载，各种图片质量都很高，很多设计师也在用；

GIF图生成工具：ScreenToGif

下面这张GIF就是我在电脑上操作的过程，是怎么生成的呢？用ScreenToGif（如果不是win10系统，若水GIF截图也非常好用哦！）

大数据指数：虫部落数据搜索

各类大数据指数工具集合网站，包括：百度指数、微信指数，有了这个就不用到处找啦。

二维码生成：草料二维码

各种精美名片在线生成、形形色色的二维码生成，非常实用；

漫画制作：暴走漫画制作器 baozoumanhua

这个小编之前也推荐很多遍了，各种丰富的暴漫表情包都在这个网站，微博运营必备~

矢量图下载：iconfont

免费矢量图下载，和PS搭配更好哦！

新媒体管家

新媒体运营小编的必备神器，记录账号后可以直接登录，不用花时间去输入密码，这个之前我也推荐过：

以上内容由数据管理平台简道云整理，不定期更新，还有哪方面需要推荐的可以在下面留言，比心~❤(｀・ω・´)❤

3. 有没有什么推荐的剪辑视频软件？

电脑配置不好的话，可以选择比较轻量级的应用比如快剪辑。

快剪辑，是一款功能齐全、操作便捷、可以在线边看边剪的免费PC端视频剪辑软件,零基础秒变视频剪辑达人。支持录制全网视频，可以在线边看边剪，无广告，永久免费。

这个软件操作起来也很简单。

1、安装好后，打开软件。

2、新建项目-选择专业模式。

3、创建新视频后，如果已将视频下载到桌面，请点击添加视频下面的本地视频。如果没有下载到桌面，而是网络上的视频，则需要将其下载到你的电脑上。

也可以直接将本地视频拖拽到软件中。

4、进行视频剪辑

编辑桌面上有很多小工具。剪刀样式是编辑工具。我们记得我们想要编辑的时间点。例如，如果我们我们想剪5-10分钟这个区域的，那么就把5分钟之前的点一下剪刀，点一下时间轨道，10分钟之后的点一下剪刀，点一下时间轨道。

然后分成三个视频片段，我们右键点击第一个片段，然后出现一个选项框，我们可以选择直接删除，第三个视频是相同的，然后保留下来的第二个视频就是我们想要的。

5、保存并导出

然后单击“保存”导出，如果想加片头片尾或者水印在这个环节就可以添加，如果不想添加，则不需要添加，然后直接按照步骤保存到桌面。

4. 怎么剪辑视频？

很高兴回答你的问题

首先，你要明确你想怎样剪辑。每个人的需求不一样，有的人说我只需剪掉视频里我不要的部分就可以了，有的人说我要为加点特效，再加个字幕，再换个背景音乐什么的，这个剪辑的方法就差很远了，一个很简单，一个就需要用很多功能了；

第二，你需要先有工具再提问。明确自己的需求了，也知道自己的视频编辑底子怎么样，就可以选择工具了，新手一般我会推荐蜜蜂剪辑，因为确实很简单，学会到做好就是半天的事情，如果你的要求很高，那肯定找专业的软件，Pr和AE都要懂，上网bd一下还是有很多教程的。

第三，不要挑学习资料。虽然你可能搜索到的答案很多介绍软件或者是广告，但实质上，除了Pr这种专业的软件，基本上你搜到的蜜蜂剪辑呀，爱剪辑呀，快剪辑呀这些基础编辑软件功能点都是那几个，你看得懂一个，也会另外几个，所以不论是文章还是视频教程，都可以去看看。

最后，我简单说说一般剪辑视频会涉及的几个步骤。你可以根据这几个功能点单独去提问，会比你问这一个那么大的问题会清晰点，也可能有人给你手把手教学。一、分割视频这也是狭义的剪辑视频，就是将一个视频去拆分几个片段，单独编辑某些片段，或者删除片段，将这些片段重新排序等等。比较常见的就是去掉视频片头片尾，去掉视频广告之类的。

二、视频基本参数调整这里包含了画面裁剪、缩放、旋转等，视频的亮度、饱和度、对比度调整等，视频的速度调整，视频原音频的音量、淡入淡出效果调整等，根据不同的需求去寻找方案。

三、添加特效这个是市面上视频编辑软件区别较大的地方，每个拥有的滤镜、叠附、转场、动画等效果不同，但如果对这部分需求不大的话，就选自己觉得操作简单的来

四、添加字幕和音乐这个需求也会比较大，因为视频组成无非就是画面+字幕+音乐，后两者都需要视频编辑软件协助完成，如果你只想添加手动输入的字幕，那就一般软件都可以做，如果你想批量添加时间线的字幕，那就要专业的添加字幕软件，如ArcTime等。

五、去水印最后想补充的还有水印的问题，一般来说添加马赛克可以解决，有些要求高的那就要用专业点的软件去抠，同一画面有几个广告的，也可以通过编辑软件p掉

目前剪辑视频需求比较多的就是以上五点，可能我回答也不够专业，因为我的水平也不是大神，只是运用了自己一些基本的视频编辑知识希望视频小白们有个大概的了解。

5. 该如何回复SCI审稿人？

如何回复SCI投稿审稿人意见（1）

1.所有问题必须逐条回答。

2.尽量满足意见中需要补充的实验。

3.满足不了的也不要回避，说明不能做的合理理由。

4.审稿人推荐的文献一定要引用，并讨论透彻。

以下是本人对审稿人意见的回复一例，仅供参考。

续两点经验：

1，最重要的是逐条回答，即使你答不了，也要老实交代；不要太狡猾，以至于耽误事；

2，绝大部分实验是不要真追加的，除非你受到启发，而想该投另外高档杂志----因为你既然已经写成文章，从逻辑上肯定是一个完整的“story” 了。

以上指国际杂志修稿。国内杂志太多，以至于稿源吃紧，基本没有退稿，所以你怎么修都是接受。

我的文章水平都不高，主要是没有明显的创新性，也很苦恼。但是除了开始几篇投在国内杂志外，其他都在国际杂志（也都是SCI）发表。以我了解的情况，我单位其他同志给国内杂志投稿，退稿的极少，只有一次被《某某科学进展》拒绝。究其原因，除了我上面说的，另外可能是我单位写稿子还是比较严肃，导师把关也比较严的缘故。

自我感觉总结（不一定对）：

1）国内杂志审稿极慢（少数除外），但现在也有加快趋势；

2）国内杂志编辑人员认真负责的人不多，稿子寄去后，少则几个月，多则一年多没有任何消息；

3）国内杂志要求修改的稿子，如果你自己不修，他最后也给你发；

4）国外杂志要求补充实验的，我均以解释而过关，原因见少帖）。还因为：很少杂志编辑把你的修改稿再寄给当初审稿人的，除非审稿人特别请求。编辑不一定懂你的东西，他只是看到你认真修改，回答疑问了，也就接受了（当然高档杂志可能不是这样，我的经验只限定一般杂志（影响因子1-5）。

欢迎大家批评指正。

我常用的回复格式，呵呵。

Dearreviewer:

Iam very grateful to your comments for the manuscript. According with youradvice, we amended the relevant part in manuscript. Some of your questions wereanswered below.

1）

2）

....

引用审稿人推荐的文献的确是很重要的，要想办法和自己的文章有机地结合起来。至于实验大部分都可以不用补做，关键是你要让审稿人明白你的文章的重点是什么，这个实验对你要强调的重点内容不是很必要，或者你现在所用的方法已经可以达到目的就行了。最后要注意，审稿人也会犯错误，不仅仅是笔误也有专业知识上的错误，因为编辑找的审稿人未必是你这个领域的专家。只要自己是正确的就要坚持。在回复中委婉地表达一下你的意见，不过要注意商讨语气哦！

我得回复格式是这样的：

DearProfessor xx:

Thankyou very much for your letter dated xxx xx xxxx, and the referees’ reports.Based on your comment and request, we have made extensive modification on theoriginal manuscript. Here, we attached revised manuscript. in the formats ofboth PDF and MS word, for your approval. A document answering every questionfrom the referees was also summarized and enclosed. A revised manuscript. withthe correction sections red marked was attached as the supplemental materialand for easy check/editing purpose. Should you have any questions, pleasecontact us without hesitate.

然后再附上Q/A，基本上嘱条回答，写的越多越好（老师语）。结果修改一次就接收了：）

我的回复，请老外帮忙修改了

DearEditor:

Thankyou for your kind letter of “......” on November **, 2005. We revised themanuscript. in accordance with the reviewers’ comments, and carefullyproof-read the manuscript. to minimize typographical, grammatical, andbibliographical errors.Here below is our description on revision according tothe reviewers’ comments. Part A (Reviewer 1). The reviewer’s comment: ......

Theauthors’ Answer: .....

2.The reviewer’s comment: ......

Theauthors’ Answer: .....

...

PartB(Reviewer 2)

1.The reviewer’s comment: ......

Theauthors’ Answer: .....

2.The reviewer’s comment: ......

Theauthors’ Answer: .....

...

Manygrammatical or typographical errors have been revised.All the lines and pagesindicated above are in the revised manuscript.

Thank you and all the reviewers for the kind advice.

Sincerely yours,

***

如何回复SCI投稿审稿人意见(2)

一个回复的例子(已接收)

Major comments:

1.The authors need to strengthen their results by including MMP secretion, andtran-matrigel migration by a positive control progenitor cell population i.e.enriched human CD34 cells obtained from mobilized PBL, since this is a moreclinically relevant source of CD34 cells which has also been shown to secreteboth MMP-9 and MMP-2 (ref. 11). CD34 enriched cells from steady stateperipheral blood which also secrete MMPs are also of interest.

2.In fig1 Cplease specify which cell line represents MMP-negative cells. Thisneeds to be clarified, as well as a better explanation of the method of theprotocol.

3.The ELISA results are represented as "fold increase" compared tocontrol. Instead, we suggest that standards should be used and results shouldbe presented as absolute concentrations and only then can these results becompared to those of the zymography.

4.When discussing the results, the authors should distinguish clearly betweenspontaneous migration vs chemotactic migration.Furthermore, the highspontaneous migration obtained with cord blood CD34 cells should be compared tomobilized PBL CD34 enriched cells and discussed.

5.The authors claim that the clonogenic assay was performed to determine theoptimum concentration for inhibition of MMP activity by phenanthroline and antiMMP-9 mAb, however they should clarify that this assay can only determine thetoxicity of the inhibitors and not their optimal inhibitory concentrations.

Minor comments:

1.There are many spelling and syntax errors, especially in the results anddiscussion, which need correction.

a.Of special importance, is the percent inhibition of migration,which isdescribed as percent of migration. i.e. pg 7:"Migration of CB CD34 wasreduced to 73.3%?" Instead should read "Migration of CB CD34 wasreduced by 73.3%?"

b.The degree symbol needs to be added to the numbers in Materials and methods.

2.It would be preferable to combine figure1Aand B, in order to confirm thereliability of fig. 1B by a positive control (HT1080).

Answer to referee 1 comment:

1.Mobilized peripheral blood is a more clinical source of CD34+ cells, so it isnecessary to compare the MMP-9 secretion and trans-migration ability of CBCD34+ cells with that of mobilized PB CD34+ cells. However, we couldn't obtainenough mobilized PB to separate PB CD34+ cells and determine the MMP-9secretion and migration ability, so we couldn’t complement the study on PBCD34+ cells in this paper. Results obtained by Janowska-Wieczorek et al foundthat mobilized CD34+ cells in peripheral blood express MMP-9.

Furthermore,Domenech’s study showed that MMP-9 secretion is involved in G-CSF induced HPCmobilization. Their conclusions have been added in the discussion. In ourpresent study, our central conclusion from our data is that freshly isolatedCD34+ stem/progenitor cells obtained from CB produce MMP-9.

2.MMP-9 negative cell used in fig1Cwas Jurkat cell. In zymographic analysis,MMP-9 was not detected in the medium conditioned by Jurkat cell. To excludethat the contaminating cells may play a role in the observed MMP-9 production, wescreened the media conditioned by different proportion of CB mononuclear cellswith MMP-9 negative cells by zymography. This result may be confusion.Actually, only by detecting the medium conditioned by 2X105 CB mononuclearcells (MNC)/ml (since the purities of CD34+ cell are more than 90%), it couldexclude the MNC role. In the revised manuscript, we only detected MMP-9activity and antigen level in the medium conditioned by 2X105 CB mononuclearcells (MNC)/ml. There is no MMP-9 secretion be detected in the mediumconditioned by 2X105 CB MNC/ml. It excluded the possibility that the MMP-9activity in CB CD34+ cells conditioned medium is due to the contamination byMNC.

3.In this revised paper, we have detected the MMP-9 antigen levels by usingcommercial specific ELISA kits (R&D System, sensitivity, 0.156ng/ml).Recombinant MMP-9 from R&D System was used as a standard. The results areexpressed in the absolute concentration. The absolute concentration result hasbeen added in the paper. As shown in Fig2, MMP-9 levels were detectable in bothCB CD34+ cell conditioned medium and BM CD34+ cell conditioned medium. However,MMP-9 level was significantly higher in CB CD34+ cell conditioned medium thanin BM CD34+ cell conditioned medium (0.406±0.133ng/ml versus 0.195±0.023ng/ml).Although gelatinolytic activity was not detected in media conditioned by CD34+cells from BM, sensitivity of ELISA favors the detection of MMP-9 antigen inthe BM CD34+.

4.In our study, to establish the direct link between MMP-9 and CB CD34+ cellsmigration, we only determined the role of MMP-9 inspontaneous migration of CBCD34+ cells, but not in chemotactic migration. Actually, regulation ofhematopoietic stem cell migration, homing and anchorage of repopulation cellsto the bone marrow involves a complex interplay between adhesion molecules,chemokines, cytokines and proteolytic enzymes. Results obtained by the groupsof Voermans reveal that not only the spontaneous migration but also the SDF-1induced migration of CB CD34+ cells is greatly increased in comparison to CD34+cells from BM and peripheral blood.

5.CD34+ cells we obtained in each cord blood sample were very limited. It is notenough to screen the inhibitors concentrations to select the optimal inhibitoryconcentrations. In the blocking experiments, based on the concentrations usedby others and the manufacturer's recommendation, we then determined theinhibitors concentrations by excluding the toxicity of the inhibitors in thatconcentration, which was determined by clonogenic assay.

Minor comments:

1.Thespelling and syntax errors have been checked and corrected.

2.Sincethe results in figure1Aand B were obtained from two separated and parallelexperiments, it is not fitness to combine two figures.

这是我的一篇修稿回复，杂志是JBMR-A,影响因子3.652,已发表，供参考！

Replyto the comments on JBMR-A-05-0172

Comment:

Reference#10 is missing from the Introduction but used much later in the manuscript.Should these be in order used in manuscript?

Reply:

Themissing reference has been added into the revised manuscript.

Comment(continued):

What is the sample size for all tests performed?

Reply:

Thesample size for drug release and PCL degradation tests was 3.0×3.0 cm2, with athickness of about0.1mmand a weight of about 40mg. This dada have been addedinto the revised manuscript.

Comment(continued):

Figure7. There is no scientific evidence presented in the TEM figure to convince thisreviewer of sub-jets. This statement on Page 9 cannot be made without clearevidence during the jet formation/separation. Figure 7 is just a large fiberand small fiber fused together, no other conclusion than this can be made.

Reply:

Necessarychange in the statements has been made in the revised manuscript. as well as inthe referred figure accordingly.

Comment(continued):

Table3: Need standard deviation for all values reported not just for a selectfew.Equation after Table 3 not necessary. Just reference method used.

Reply:

Done accordingly.

Comment(continued):

Page11: "faster weight loss" What was the sample size? Where is thestatistical analysis of this data? This reviewer does not see a significantdifference in any of the data presented, thus weight loss would be consideredequivalent.

Reply:

Althoughnot too much difference was seen, the conclusion that “the GS/PCL membraneexhibited a relatively faster weight loss compared with the RT/PCL membrane”was indeed applicable through “one-way analysis of variance (ANOVA)” analysis.Following the reviewer’s comment, a new sub-section has been added to themanuscript. to address the statistical analysis for the data.

Comment(continued):

Page12: What is the sample size for release data? Looks like results based on asample size of one? Need stand deviations on the data presented in Figure 11.Why wasn't release

performedand compared for all electrospun conditions investigated otherwise?

Reply:

Threerepeated tests were performed for each set of measurements and the resultingdata were averaged. As stated in the revised manuscript, each sample had asquare area of 33cm2 with a slightly different thickness.Standarddeviations have been added to the data shown in Fig. 11.The present manuscript.aimed to show that medical drugs can be encapsulated in ultrafine fibersthrough a co-axial electrospinning process. The drug release data intended toshow that the encapsulation was successful. We did not consider any specificapplication in this preliminary paper, and in fact the two drugs were justchosen as model illustration. As such, there seemed not necessary to perform.release experiments for all of the membranes electrospun with differentconditions (i.e. the core concentrations)

Comment(continued):

Table3: Yang's or Young's Modulus (page 10 says Young's).

Reply:

Corrected accordingly.

Comment(continued):

Figure11: What is the % release, not just concentration. Why just this small sampleof release data? Where is the release data for the other conditions?

Reply:

Unfortunately,we did not measure the amount of the shell material in obtaining the compositenanofibers. Namely, the flow rate of the shell solution during theelectrospinning was not accurately controlled using an injecting pump. Hencethe % release was not applicable. Please refer to the previous reply related toPage 12 and Figure 11 for the remaining comments.We acknowledge the reviewer’scomments and suggestions very much, which are valuable in improving the quality of our manuscript.

SCI生物医学英文论文发表成功经验发表成功经验

SCI生物医学英文论文发表成功经验共享系列一---（Clinical Chemistry）

将自己近10年的科研工作中有关论文整理总结发表方面的一些信息贡献出来，与大家共享！如有时间，我拟将一些已经发表的文章，按照撰写与发表的实际经历与过程，即通过案例分析每一个杂志的特色，审稿偏好，review意见及答复要点等逐一分析。可能包含的杂志系列有：naturemethods，clinical chemistry，analyticalchemistry，J. Clin. Immuno，Biomed. Microdev，Front.Biosci，Mol. Cell. Biochem，J.Expert，Rev. Proteomics，Jbiochemistry等。

本章先讲解美国ClinicalChemistry杂志，一个临床化学界的王牌杂志，近年其影响因子逐年攀升，现为7.7分。Clinical Chemistry由美国AACC每月出版，接受的文章包括与人体疾病相关的实验室研究，分析与分子诊断，仪器，资料处理，数据分析，临床研究等投稿。ISSN：0009-9147网络版ISSN：1530-8561

【URL】http://intl.clinchem.org/

【镜像URL】http://www.clinchem.org/

【出版者】AmericanAssociation for Clinical Chemistry (AACC)

【收费情况】免费,全文

【内容简介】

ClinicalChemistry is an international journal of laboratory medicine and moleculardiagnostics.Clinical Chemistry -- This highly respected and often-citedscientific journal is published monthly and contains peer-reviewed methodology,research papers and other articles relevant to clinical chemistry and relatedlaboratory sciences. Its circulation is more than 15,000.David E. Bruns, MD,Editor, (Charlottesville Office)

dbruns@clinchem.aacc.org

SandraWeaver, Senior Editorial Assistant

sweaver@clinchem.aacc.org

DonnaBrandl, Editorial Assistant

dbrandl@clinchem.aacc.org

ShaneP. Cyr, Editorial Assistant

scyr@clinchem.aacc.org

MacFancher, Publisher, (WashingtonOffice)

mfancher@aacc.org

MiriamGonzalez, Publications Coordinator

mgonzalez@aacc.org

【目录、摘要或全文上网等情况】

FreeTOC, 1965 -

Free Abstract, 1975 -

FreeFulltext, 1997 -1999

Fulltext,1997 -

【杂志被索引的情况】

Indexedin Chemical Abstracts.

【备注】

Forfaster access to Clinical Chemistry Online from these countries use this URL:

http://intl.clinchem.orgAustralia, Brazil,China, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan,Mexico,Russia, Singapore, South Africa, South Korea, Spain, Sweden,Switzerland, Taiwan, The Netherlands, UK该杂志是由美国临床化学协会（AmericanAssociation for Clinical Chemistry，AACC）主办的，于1948年成立，总部位于华盛顿，拥有1万余会员。先在网站注册，登记，按照提示一步步提供文章名称，摘要，作者姓名，所属领域，关键词，主文，图表等等。转换为PDF后就可以提交，然后给你一个查询号，接着就是等待了。。。

等了20多天，查阅状态看到了第一次回信：

HomeAuthor Area Reviewer Area Personal Info. ClinChem Home Sign Out Submit NewManuscript. Information for Authors Queue Summary Feedback Help FAQ

DecisionLetter

[Returnto Queue]

To:作者姓名（电子邮件）

From:clinchemed@clinchem.aacc.org

Subject:Clinical Chemistry -- Manuscript. Decision

Cc:

RE:Clinical Chemistry MS ID# CLINCHEM/2002/036332

TITLE:

Dear Dr. xxx:

Yourmanuscript. has been examined by two expert reviewers. Please visit http://submit.clinchem.org to view their comments. For thereasons detailed in these comments, we cannot accept this manuscript. forpublication in Clinical Chemistry in this form. Also, your Reference 28 is notformatted properly. Our Information for Authors will offer assistance withjournal style; it can be found athttp://www.aacc.org/ccj/infoauth.stmWe would consider a revised version thattakes these criticisms into account. If you should resubmit the paper I wouldalso ask that you have several English speaking colleagues proof the paper forgrammar and composition. Additionally, be sure to provide a detailedpoint-by-point response to the comments of the reviewers. Failure to do so willdelay consideration of the revised manuscript.Prior to publication we requirecopyright releases signed by all authors. Our Authors Assurances and Assignmentof Copyright form. can be downloaded from http://www.aacc.org/ccj/auth_assure02.pdf. Please note that all authors must signboth sections of the form. (a signature on the lower section means that allconflicts of interest have been disclosed even if there are none). Send thecompleted form. to us by FAX (434-979-7599).

Sincerely,

Dr.xxx nesley

Associate Editor

P.S.You will find your revised manuscript. can be uploaded in your "Submit aRevision" queue at http://submit.clinchem.org. Please do not begin the submission ofyour revised manuscript. until you are ready to submit the entire manuscript. Achecklist regarding requirements for submission can be found athttp://www.aacc.org/ccj/manuscript_check02.pdf. Figures must be uploaded as ImageFiles in .tif or .eps files at 600 DPI. Alternatively, you may use PowerPointsoftware for figures but fonts must be embedded and only one image per slide,one slide per file. When uploading the revised version, please be sure toinclude in the "Response to Reviews" field a point-by-point list ofall changes made, or your rebuttal, in response to each of the reviewers?

suggestions.

P.P.S.Please note that if your manuscript. has color figures, the authors areexpected to bear the cost of printing them, except in the case of invitedpapers. The charges for these figures are $1500 for the first color figure orpart of a figure, and $500 for each additional color figure or part of afigure. Authors will be billed for color publication costs unless they requestthat their figures be printed in black and white.

该杂志一般为2个审稿人，审稿过程也较严格，都是本领域的大牛。后来我还有幸在一次会议上认识到一个当年的审稿人，但不知道是1还是2，呵呵！一般总是先鼓励一段话，不写了。。。

下面问题就来了，共12个，有些很好回答，一句话就可以解释清楚，有些就比较麻烦。还是举例说明把

--------------------------------------------------------------------------------------

1）实验的有效性和深度（at least for a few substances of major importance

detectionlimits, cut-off values and specificity should have been studied.Also the description of the assay principle is not quite clear）

没办法，只有一条路，补充相关实验，然后再投。

2）语言问题（The English text would have to be substantially improved）

虽然这是一个美国杂志，但对语言的要求一点都不弱，投之前还是忽略了，没办法，慢慢修改。

3）核心的技术问题（A cut-off value is given for MOL but the dimension is missing. Inthe discussion various anecdotic reports are given for which no data arepresented under results.）重新验证讨论。本来认为很快就可以接受了，没想到却又等了一个半月（中间发过一次信件询问）才收到回信。原来除了上次2个评委，这次又增加了一个独立审稿人。。。

原文如下：

Yourrevised manuscript. has been examined by the original two reviewers, plus arecommended third reviewer with special expertise in this area. Please visit http://submit.clinchem.org to retrieve their comments. The threereviewers find merit in the work, but have numerous constructive suggestions（别害怕，其实就是几个小问题）. Please consider these suggestions carefully and prepare animproved version that addresses these concerns. I have also noted that thereare several color figures included in the paper, which seem to be useful onlyin color. Please be aware that (should your paper be accepted for publication)authors are expected to pay the costs for publication of color figures. Thecharge for the first color figure is $1500; subsequent figures, or parts offigures, are $500 each. Of course, if you wish to submit alternate figures inblack and white (or grayscale), you may do so.

Sincerely,

Dr.xxx

Associate Editor

P.S.You will find your revised manuscript. can be uploaded in your "Submit aRevision" queue at http://submit.clinchem.org. A checklist of requirements forsubmission can be found at http://www.aacc.org/ccj/manuscript_check02.pdf. When uploading the revised version,please be sure to include in the "Response to Reviews" field apoint-by-point list of all changes made, or your rebuttal, in response to eachof the reviewer suggestions. Also, please submit copyright releases for allauthors. Our Authors' Assurances and Assignment of Copyright form. can bedownloaded from http://www.aacc.org/ccj/auth_assure02.pdf. Please note that all authors must signboth sections of the form. Send the completed form. to us by FAX(434-979-7599).P.P.S. For figures, please submit .tif files that have a minimumresolution of 600 DPI; the width and height of the Pixels should be about 4200x 4200. Alternatively, you may use PowerPoint for figures, but each .ppt filemay contain only one slide and fonts must be embedded.

总之一句话，还是需要再次修改。

又等了接近1个月时间，幸亏不是学生赶毕业，最终被接收了。

Thank you for your revised manuscript. It is acceptable and will be processed forpublication. Please note that I edited the paper to remove all text related toFigure 6. The structures of the drugs are available to anyone who wants to lookthem up. Thus this figure will not be in the proofs that you receive.

如果proof快的话，这个杂志一般会安排在2-3个月后发表。

If page proofs are returned promptly, your paper is scheduled to appear in the Octissue.之前电子版会先在网上发布Papers in press are posted online 2-6 weeks before the issue date.Issues are scheduled to be mailed to subscribers and appear on the Internetbefore the first day of the issue month. The electronic version (http://www.clinchem.org)is published at Stanford University's HighWire Press, where your article willbe linked electronically to and from PubMed and directly to and from over 340other journals that are on-line at Stanford.当然还要转移版权Priorto publication we require copyright releases signed by all authors. Our AuthorsAssurances and Assignment of Copyright form. can be downloaded from http://www.aacc.org/ccj/auth_assure02.pdf. Please note that all authors must signboth sections of the form. (a signature on the lower section means that allconflicts of interest have been disclosed even if there are none).

Thankyou for this contribution.

Sincerely,

Dr.xx

Associate Editor

我们的回复

DearDr.×××,

Thankyou very much for giving me an opportunity to revise the abovemanuscript.

Accordingto the reviewers' comments, we have revised the manuscript to provided ourexplanation.

Furthermore,we revised the paper according to your suggestion.

1)The length of abstract is 194 words, and the word of the main text is2550.

2)The layout and format guidelines have been followed.

3)The changes to the paper have been highlighted underlined as well as includingdetailed responses to the reviewers comments.